Michael A Schwarzschild, MD, PhD

Job title:
Director, Molecular Neurobiology Laboratory
Organization:
Massachusetts General Hospital
PD Guide Terms:
Etiology
Risk Factors
Biological Features
Disease Modification
Pathogenic Mechanisms
Compensatory & Neuronal Health Mechanisms
PD Subtypes
Disease Progression
Clinical & Biological Features
Therapeutic Development
Investigative Tools
Contributions:
Published Contributions:
Response to Andy Grove re: ADAGIO
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
13 Oct 2009 04:22 PM EST
I think I understand where you’re coming from about the slopes but it’s hard to be sure by email. [Note: Dr. Schwarzschild has approved this posting of his email response to Dr. Grove, ... 
We must do better (with rasagiline so far no better than levodopa as a disease-modifying therapy?)
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
29 Sep 2009 05:40 PM EST
These recent rasagiline data (Olanow et al., 2009) represent a laudable if not heroic effort on behalf of PD patients, but unfortunately they are inconclusive and  I believe they do not warrant ... 
Responses: 4
Why target urate in PD?
Dietary Factors
21 Sep 2009 05:26 PM EST
A recent confluence of evolutionary, laboratory, epidemiological and clinical data has identified urate or one of its determinants as a promising target in the development of neuroprotective therapy ...